Amol Akhade: Polestar vs Laura – What’s your pick?
Amol Akhade posted the following on LinkedIn:
“Polestar vs Laura? Third-generation TKI post CTRT for stage 3 NSCLC in EGFR mutated patients.
Aumolertinib vs Osimertinib.
What’s your pick?
Laura for me. Control arm of Polestar has underperformed as compared to that of Laura. There is a difference in PET scan-based staging in two studies. Polestar is probably a ‘me too’ study. It won’t change practice in the rest of the world.
What do you think?”
Source: Amol Akhade/LinkedIn
More posts featuring Amol Akhade on oncodaily.com
Dr. Amol Akhade is a senior consultant medical oncologist and hemato-oncologist. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital. He specialises in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplant. Currently, he is a Consultant Medical Oncologist at Suyog Cancer Clinics and Reliance Hospitals.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023